Seroquel XR in Schizophrenia Relapse Prevention

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00990626
First received: October 1, 2009
Last updated: November 16, 2010
Last verified: November 2010
  Purpose

The purpose of the study is to determine whether the Seroquel XR treatment for 6 months improve the relapse prevention in schizophrenic outpatients


Condition
Schizophrenia Relapse Prevention

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Seroquel XR in Schizophrenia Relapse Prevention

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Rate of patients remained relapse free after 6 months of treatment [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Adherence rate of patients [ Designated as safety issue: No ]
  • Quality of Life (QoL ) [ Designated as safety issue: No ]

Estimated Enrollment: 1600
Study Start Date: October 2009
Study Completion Date: July 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
Schizophrenic outpatients

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Psychiatric outpatient clinics

Criteria

Inclusion Criteria:

  • Schizophrenic outpatients on at least 600 mg Seroquel XR treatment for at least 1 month

Exclusion Criteria:

  • Severe cerebro- and cardiovascular disease, severe hepatic impairment, gravidity
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00990626

Locations
Hungary
Research Site
Baja, Hungary
Research Site
Barcs, Hungary
Research Site
Budapest, Hungary
Research Site
Cegled, Hungary
Research Site
Debrecen, Hungary
Research Site
Dombovar, Hungary
Research Site
Dunaujvaros, Hungary
Research Site
Eger, Hungary
Research Site
Egerszalok, Hungary
Research Site
Emod, Hungary
Research Site
Erd, Hungary
Research Site
Esztergom, Hungary
Research Site
Godollo, Hungary
Research Site
Gyongyos, Hungary
Research Site
Gyor, Hungary
Research Site
Gyula, Hungary
Research Site
Heves, Hungary
Research Site
Hodmezovasarhely, Hungary
Research Site
Janoshalma, Hungary
Research Site
Jaszbereny, Hungary
Research Site
Kalocsa, Hungary
Research Site
Kecskemet, Hungary
Research Site
Ketegyhaza, Hungary
Research Site
Kiskunhalas, Hungary
Research Site
Kistokaj, Hungary
Research Site
Miskolc, Hungary
Research Site
Nagyatad, Hungary
Research Site
Nagykallo, Hungary
Research Site
Nagykanizsa, Hungary
Research Site
Nagykoros, Hungary
Research Site
Oroshaza, Hungary
Research Site
Pecs, Hungary
Research Site
Pomaz, Hungary
Research Site
Satoraljaujhely, Hungary
Research Site
Soltvadkert, Hungary
Research Site
Sopron, Hungary
Research Site
Sumeg, Hungary
Research Site
Szeged, Hungary
Research Site
Szeghalom, Hungary
Research Site
Szekesfehervar, Hungary
Research Site
Szekszard, Hungary
Research Site
Szentes, Hungary
Research Site
Szigetszentmiklos, Hungary
Research Site
Szigetvar, Hungary
Research Site
Szolnok, Hungary
Research Site
Szombathely, Hungary
Research Site
Tatabanya, Hungary
Research Site
Veszprem, Hungary
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Attila Németh National Psychiatric Centre
Study Chair: Lilla Szabó AstraZeneca Hungary MC
Study Director: Tamás Bábel AstraZeneca Hungary MC
  More Information

No publications provided

Responsible Party: MC MD, AstraZeneca
ClinicalTrials.gov Identifier: NCT00990626     History of Changes
Other Study ID Numbers: NIS-NHU-SER-2009/1
Study First Received: October 1, 2009
Last Updated: November 16, 2010
Health Authority: Hungary: National Institute of Pharmacy

Keywords provided by AstraZeneca:
Seroquel XR
schizophrenia relapse prevention

Additional relevant MeSH terms:
Recurrence
Schizophrenia
Disease Attributes
Pathologic Processes
Schizophrenia and Disorders with Psychotic Features
Mental Disorders
Quetiapine
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Psychotropic Drugs

ClinicalTrials.gov processed this record on April 15, 2014